drugset / Trial / NCT05313906
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
Phase 2
Unknown
40 enrolled
Henan Cancer Hospital
Rongchang Biopharmaceutical · collabZhengda Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
Timeline
- Start
- 2022-05-07
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | — | — |
| Subject | Penpulimab | Monoclonal antibody | — | — |